IL166423A0 - Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies - Google Patents

Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Info

Publication number
IL166423A0
IL166423A0 IL16642303A IL16642303A IL166423A0 IL 166423 A0 IL166423 A0 IL 166423A0 IL 16642303 A IL16642303 A IL 16642303A IL 16642303 A IL16642303 A IL 16642303A IL 166423 A0 IL166423 A0 IL 166423A0
Authority
IL
Israel
Prior art keywords
erb
kinase inhibitors
therapeutic combinations
antineoplastic therapies
antineoplastic
Prior art date
Application number
IL16642303A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL166423A0 publication Critical patent/IL166423A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16642303A 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies IL166423A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11
PCT/IB2003/003388 WO2004014386A1 (en) 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Publications (1)

Publication Number Publication Date
IL166423A0 true IL166423A0 (en) 2006-01-15

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16642303A IL166423A0 (en) 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Country Status (17)

Country Link
US (2) US20040067942A1 (enExample)
EP (1) EP1549320A1 (enExample)
JP (1) JP2005538129A (enExample)
CN (1) CN1674908A (enExample)
AR (1) AR040792A1 (enExample)
AU (1) AU2003249450A1 (enExample)
BR (1) BR0313470A (enExample)
CA (1) CA2494270A1 (enExample)
IL (1) IL166423A0 (enExample)
MX (1) MXPA05001430A (enExample)
NO (1) NO20051170L (enExample)
PA (1) PA8578001A1 (enExample)
PE (1) PE20040990A1 (enExample)
PL (1) PL375414A1 (enExample)
RU (1) RU2005102836A (enExample)
TW (1) TW200404532A (enExample)
WO (1) WO2004014386A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
UA88008C2 (en) 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
BRPI0511800A (pt) * 2004-06-03 2008-01-15 Hoffmann La Roche tratamento com irinotecano (cpt-11) e um inibidor de egfr
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
KR100986945B1 (ko) * 2004-06-03 2010-10-12 에프. 호프만-라 로슈 아게 젬시타빈 및 ｅｇｆｒ-억제제로의 치료
JP2008501708A (ja) * 2004-06-04 2008-01-24 スミスクライン ビーチャム （コーク） リミテッド がんの治療方法
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
RU2325199C2 (ru) * 2006-06-20 2008-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения местно-распространенных форм рака шейки матки
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
JP2014514359A (ja) * 2011-05-06 2014-06-19 メリマック ファーマシューティカルズ インコーポレーティッド 抗ＥｒｂＢ３剤を含む併用治療において有毒な薬物相互作用を予防するための方法
WO2021178789A1 (en) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of different cancerous disorders
CN118576601A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗结肠癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
KR20030068205A (ko) * 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법

Also Published As

Publication number Publication date
CN1674908A (zh) 2005-09-28
BR0313470A (pt) 2005-06-21
RU2005102836A (ru) 2005-08-10
US20060293323A1 (en) 2006-12-28
US20040067942A1 (en) 2004-04-08
WO2004014386A1 (en) 2004-02-19
PE20040990A1 (es) 2004-12-27
CA2494270A1 (en) 2004-02-19
JP2005538129A (ja) 2005-12-15
NO20051170L (no) 2005-05-06
PL375414A1 (en) 2005-11-28
PA8578001A1 (es) 2004-05-07
TW200404532A (en) 2004-04-01
EP1549320A1 (en) 2005-07-06
MXPA05001430A (es) 2005-06-06
AU2003249450A1 (en) 2004-02-25
AR040792A1 (es) 2005-04-20

Similar Documents

Publication Publication Date Title
PL375414A1 (en) Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies
EP1539129A4 (en) DOSAGE FORMS AND RELEVANT THERAPIES
PL403456A1 (pl) Pochodne 5-fenylotiazolu oraz ich zastosowanie jako inhibitorów kinazy Pi3
AU2003256410A8 (en) Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
EP1501514A4 (en) PROTEIN-KINASE MODULATORS AND METHODS OF USE
AU2003303128A8 (en) Inhibitors and methods of use thereof
PH12012501372A1 (en) Proteasome inhibitors and methods of using the same
PL372620A1 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
PL374598A1 (en) Caspase inhibitors and uses thereof
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
ZA200600176B (en) Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
PL369005A1 (en) Combinations comprising cox-2 inhibitors and aspirin
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
ZA200601293B (en) Proteasome inhibitors and methods of using the same
SI1648905T1 (sl) Inhibitorji tienopiridin- in furopiridin kinaze
EG24845A (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
AU2003257043A8 (en) Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003251513A8 (en) Rsk inhibitors and therapeutic uses thereof
AU2003245627A8 (en) Kinases and phosphatases
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
ZA200501026B (en) Therapeutic combinations of erb B kinase inhibitors and antineoplastic therapies